CSL Vifor proposes solution for Pharmacosmos dispute

CSL Vifor is proposing a marketing campaign in nine EU countries and to refrain from commenting on Pharmacosmos’ drug safety profile for ten years, thus closing the European competition inquiry.
Australian CSL acquired Vifor Pharma in late 2021 in a deal worth USD 11.7bn and changed the company's name to CSL Vifor in August 2022. | Photo: CLS Vifor/PR
Australian CSL acquired Vifor Pharma in late 2021 in a deal worth USD 11.7bn and changed the company's name to CSL Vifor in August 2022. | Photo: CLS Vifor/PR

Australian-Swiss CSL Vifor is now trying to put an end to a European competition investigation that came about after Pharmacosmos filed a complaint with the European Commission.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading